Fibrinogen, a cardiovascular risk factor

Ernst, E

doi:10.1016/0021-9150(94)94365-6

Cited by 7 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fibrinogen has long been considered a cardiovascular risk factor [20] , and a recent meta-analysis has confirmed this view [21] . Moreover, plasma fibrinogen levels have been found to be associated with an increased risk of femoral plaque [8] .…”

Section: Discussionmentioning

confidence: 72%

Fibrinogen Apheresis in the Treatment of Peripheral Arterial Disease

Ramunni¹,

Brescia²,

Quaranta³

et al. 2007

Blood Purif

View full text Add to dashboard Cite

Background: Fibrinogen is mainly responsible for determining the viscosity of whole blood. In peripheral arterial disease (PAD) the fibrinogen concentration seems to affect the microcirculation flow. Aim: To study the effects of an abrupt reduction of fibrinogen on the hemodynamics of the lower extremities and the clinical picture of patients with PAD. Methods: Ten patients affected by various stages of PAD underwent 1 session of fibrinogen apheresis (TheraSorb, Miltenyi Biotec, Germany). Laboratory parameters of endothelial activation were assessed before and after the session, as well as walking distance (WD), the ankle-brachial index and laser Doppler flowmetry. Results: A significant reduction in the laboratory parameters was observed: fibrinogen (50%), total cholesterol (18%), LDL cholesterol (24%), sE-selectin (23%), sICAM-1 (19%) and sVCAM-1 (10%). The procoagulant factors, factor VIII and von Willebrand factor, did not vary significantly. Both pain-free and total WD were significantly improved (p < 0.003 and p <0.006, respectively), the ankle-brachial index remained unchanged, and laser Doppler flowmetry showed a modest but not significant increase. Conclusions: Fibrinogen apheresis allowed us to study the effects of an acute modification of fibrinogen in PAD, on both some aspects of the endothelial function and on the hemodynamics, demonstrating an improvement of WD and a minimal increase in the skin microcirculation.

show abstract

Section: Discussionmentioning

confidence: 72%

Fibrinogen Apheresis in the Treatment of Peripheral Arterial Disease

Ramunni¹,

Brescia²,

Quaranta³

et al. 2007

Blood Purif

View full text Add to dashboard Cite

show abstract

“…Since the publication of a previous meta-analysis of 6 prospective studies of baseline fibrinogen levels that included 845 cases of CHD, 50 several of those studies have published additional follow-up, and several others have been published for the first time. Eighteen prospective studies of fibrinogen have now been identified (including 6 studies in patients with either angina or myocardial infarction at baseline), involving a total of 4018 CHD cases with a weighted mean age at baseline of 56 years and a weighted mean follow-up of 8 years [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22] ( Figure 1).…”

Section: Fibrinogenmentioning

confidence: 98%

Association of Fibrinogen, C-reactive Protein, Albumin, or Leukocyte Count With Coronary Heart Disease

Danesh¹,

Collins²,

Appleby³

et al. 1998

JAMA

1,911

1,267

View full text Add to dashboard Cite

“…Some infections may predispose individuals to hypertension; for example, Helicobacter pylori and C. pneumonia infections were found to have a role in hypertension (7). In infections such as CCHF, increased prothrombotic factors, particularly fibrinogen, fibrin D-dimer (a fragment of cross-linked fibrin and a marker of thrombosis) and anti-cardiolipin antibodies may lead to hypertension (8)(9)(10)(11). The pathogenesis of concurrent hypertension during CCHF is not completely understood.…”

Section: Discussionmentioning

confidence: 99%